Radiofrequency Ablation for BIII Thyroid Nodules

Launched by COLUMBIA UNIVERSITY · Dec 28, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called Radiofrequency Ablation (RFA) for patients with certain types of thyroid nodules known as indeterminate Bethesda III nodules. These nodules are not clearly benign or malignant, so the trial aims to gather information on how effective and safe RFA is for treating them. The RFA procedure involves using a special tool to deliver heat to the nodule, helping to shrink or destroy it. This study involves collecting data from patients both before and after they undergo the RFA treatment.

To participate in the trial, patients should have indeterminate Bethesda III nodules that have been tested and found to be benign using specific genetic tests. The study is open to adults aged 65 to 74, and both men and women can join. However, individuals with certain heart conditions or those who are pregnant cannot participate. Those who take part can expect to have their medical information reviewed before and after the RFA procedure to help researchers understand how well it works and if it is safe.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Indeterminate Bethesda III nodules that have been molecularly profiled benign with either Afirma Genomic Sequencing Classifier (GSC) or ThyroSeq v3 tests
• Exclusion Criteria:
• • cardiac arrthymias
• • pregnancy